Physician profile
Salil Gupta
NPI 1316041551
$2,166.48
in general payments reported to CMS, 2019-2025
21 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $131 · 2021: $153 · 2022: $640 · 2023: $406 · 2024: $373 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.90 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $277.17 | 2022-2023 | |
| Amgen INC. | $253.29 | 2019-2025 | Tavneos |
| Glaxosmithkline, LLC. | $251.31 | 2022-2023 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $219.48 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $193.83 | 2019-2020 | |
| Medtronic, INC. | $156.25 | 2021-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $134.63 | 2022-2025 | Farxiga |
| Ardelyx, INC. | $123.48 | 2024 | Xphozah 30 Mg |
| Vifor Pharma, INC. | $105.49 | 2021-2022 | |
| Abbott Laboratories | $93.06 | 2021-2025 | Freestyle Libre 3, Architect |
| Ani Pharmaceuticals, INC. | $79.50 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $52.76 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $44.09 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $33.91 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.44 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.76 | 2019 | |
| Calliditas Therapeutics US INC. | $21.75 | 2022 | |
| Baxter Healthcare | $20.64 | 2023 | Renal - Pd |
| Nxstage Medical, INC. | $18.65 | 2023 | Nxstage System One, Pureflow Sl |
| Genentech USA, INC. | $17.85 | 2020 | |
| Novo Nordisk INC | $16.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.